International Clinical Guidelines: Convergence Against Activation Therapy
The convergence of major national and international guidelines against graded exercise therapy (GET) and toward energy management represents one of the clearest policy shifts in ME/CFS history. The NICE 2021 guideline (United Kingdom) marked a watershed by explicitly withdrawing its prior recommendation for GET and stating that CBT is not curative for ME/CFS (National Institute for Health and Care Excellence 2021). The guideline recommends individualised energy management and explicitly warns against exercise programmes that do not accommodate post-exertional malaise. The DEGAM 2022 S3-Leitlinie Müdigkeit (Germany)—issued by the Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin, the primary German GP professional society—recommends using the IOM criteria for initial screening and the Canadian Consensus Criteria for diagnostic confirmation (Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin 2022). The guideline explicitly warns against “activating measures” (aktivierende Maßnahmen), adopting language that directly contradicts the earlier European rehabilitation paradigm. Pacing and energy management are recommended as the primary non-pharmacological approach. The EUROMENE consensus (European Network on ME/CFS) provides coordinated European guidance on diagnosis, service provision, and care (Nacul et al. 2021). It emphasises PEM as the distinguishing clinical feature and advocates for interdisciplinary care models. At the policy level, the German Gemeinsamer Bundesausschuss (G-BA, Joint Federal Committee) established the LongCOV-RL in 2023—a statutory care guideline under §92 SGB V that mandates structured, needs-based care for Long COVID and ME/CFS following SARS-CoV-2 infection (Gemeinsamer Bundesausschuss 2023). Unlike advisory guidelines, this directive carries regulatory force: it establishes GP-coordinated multi-level care pathways, requires specialist referral for complex cases, and includes specific provisions for PEM assessment. The guideline includes a three-year evaluation mandate to assess effectiveness using patient care data and emerging research. This represents one of the first statutory (not advisory) care frameworks for ME/CFS-spectrum conditions in any jurisdiction. The direction of travel is unambiguous: every major guideline revision since 2020 has moved away from activation-based therapy and toward recognition of PEM as a central clinical feature requiring energy management, not exercise escalation.